Naghma Batool
Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur, Rajasthan, India
Mukesh Bansal
Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur, Rajasthan, India
Dilip Agrawal
Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur, Rajasthan, India
Abstract
Major depression extremes of affective disorders which refer to a pathological change in the mood state. Major depressive disorder is associated with substantial morbidity, mortality, family burden, and health care costs. Since no single treatment is uniformly effective,2-4 subsequent interventions are often needed. Secondstep treatments include augmenting the first agent with a second or discontinuing the first agent and beginning a second (switching). The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial used an equipoise, stratified, randomized design to evaluate the relative efficacy and tolerability of various antidepressant treatments for outpatients with non psychotic major depressive disorder who had a lack of remission or could not tolerate the selective serotonin-reuptake inhibitor (SSRI) citalopram (Celexa, Forest Pharmaceuticals) or subsequent treatments. The mood change may have a psychotic basis with delusional thinking or 0ccur in isolation and induce anxiety. On the other hand, pathological anxiety may lead to depression anxiety and depression are leading psychiatric disorder now.
Antidepressant these are drugs which can elevate mood in depressive illness. Practically all antidepressant affect monomaniergic transmission in the brain in one way or the other, of them have associated properties. It is typically a third- or fourth-line agent. It has a unique pharmacology, inhibiting the reuptake of noradrenaline Bupropion has been used as an antidepressant for over 20 years, though its licence for such use varies and dopamine, potentially providing pharmacological augmentation to more common antidepressants such as selective serotonergic reuptake inhibitors (SSRIs). This systematic review and meta-analysis identified 51 studies, dividing into four categories: bupropion as a sole antidepressant, bupropion coprescribed with another antidepressant, bupropion in ‘other’ populations (e.g. bipolar depression, elderly populations) and primary evaluation of side effects.
Keywords: antidepressant; depression; selective serotonin reuptake inhibitors